Clicky

Instil Bio, Inc.(TIL)

Description: Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.


Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Oncology Cancer Immunotherapy Cell Therapy Non Small Cell Lung Cancer Melanoma Cervical Cancer Lymphocytes Squamous Cell Carcinoma Head And Neck Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma Therapies For The Treatment Of Patients With Cancer Tumor Infiltrating Lymphocytes

Home Page: instilbio.com

TIL Technical Analysis

3963 Maple Avenue
Dallas, TX 75219
United States
Phone: 972 499 3350


Officers

Name Title
Mr. Bronson Crouch Chairman & CEO
Dr. Sandeep Laumas M.D. CFO & Chief Bus. Officer
Mr. Timothy L. Moore Chief Operating Officer
Dr. Mark E. Dudley Ph.D. Chief Scientific Officer
Ms. Sumita Ray J.D. Chief Legal, Compliance, & Admin. Officer
Dr. Robert Hawkins MBBS, Ph.D. Head of R&D

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3027
Price-to-Sales TTM: 55329.793
IPO Date: 2021-03-19
Fiscal Year End: December
Full Time Employees: 412
Back to stocks